The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.

por Gábor Szalóki, Zoárd T Krasznai, Ágnes Tóth, Laura Vízkeleti, Attila G Szöllősi, György Trencsényi, Imre Lajtos, István Juhász, Zoltán Krasznai, Teréz Márián, Margit Balázs, Gábor Szabó, Katalin Goda
Publicado 2014